XML 52 R41.htm IDEA: XBRL DOCUMENT
v3.25.3

Loss Per Common Share (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Earnings Per Share [Abstract] |
Schedule of Computation of Basic and Diluted Earnings Per Share | The following table sets forth the computation of basic and diluted earnings per share available for common stockholders (in thousands, except per share data):
| For the Three Months Ended September 30, |  | For the Nine Months Ended September 30, |
| 2025 |  | 2024 |  | 2025 |  | 2024 |
Loss before preferred dividends and accretion of Series A Preferred Stock including excise tax | $ | (20,864) |  |  | $ | (23,137) |  |  | $ | (105,379) |  |  | $ | (38,821) |  |
Dividends and accretion of Series A Preferred Stock including excise tax | (6,066) |  |  | (8,094) |  |  | (44,891) |  |  | (24,018) |  |
Net loss attributable to common shareholders of Evolent Health, Inc. | $ | (26,930) |  |  | $ | (31,231) |  |  | $ | (150,270) |  |  | $ | (62,839) |  |
Weighted-average common shares outstanding - basic and diluted | 114,066 |  |  | 114,862 |  |  | 115,083 |  |  | 114,565 |  |
Loss per common share |  |  |  |  |  |  |  |
Basic and diluted | $ | (0.24) |  |  | $ | (0.27) |  |  | $ | (1.31) |  |  | $ | (0.55) |  |
Schedule of Antidilutive Securities Excluded From Computation of Earnings Per Share | Anti-dilutive shares excluded from the calculation of weighted-average common shares presented above are presented below (in thousands):
| For the Three Months Ended September 30, |  | For the Nine Months Ended September 30, |
| 2025 |  | 2024 |  | 2025 |  | 2024 |
Restricted stock units (“RSUs”), performance-based RSUs (“PSUs”) and leveraged stock units (“LSUs”) | 1,257 |  |  | 804 |  |  | 744 |  |  | 782 |  |
Stock options | — |  |  | 230 |  |  | — |  |  | 309 |  |
Series A Preferred Stock | 1,807 |  |  | 4,375 |  |  | 3,510 |  |  | 4,375 |  |
Convertible senior notes | 19,336 |  |  | 20,252 |  |  | 16,960 |  |  | 20,252 |  |
Total | 22,400 |  |  | 25,661 |  |  | 21,214 |  |  | 25,718 |  |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details
Name: | us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration